Author Correction: miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR–p-PI3K/AKT-c-JUN

Zhao, Mengyang; Luo, Rong; Liu, Yiyi; Gao, Linyuan; Fu, Zhaojian; Fu, Qiangqiang; Luo, Xiaojun; Chen, Yiyu; Deng, Xiaojie; Liang, Zhonglin; Li, Xin; Chen, Cheng; Liu, Zhen; Fang, Weiyi

doi:10.1038/s41467-021-22959-7

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhao et al recently corroborated these observations, highlighting a significant role of miR-3188 in the emergence of drug resistance during chemotherapeutic treatment. They linked this resistance to the impact of miR-3188 on signal transduction along the mTOR/PI3K/AKT/c-JUN pathway [ 83 ]. Therefore, results obtained by us suggest the nuanced role of miRNA molecules, which should not be solely regarded as negative expression regulators but also as enhancers.…”

Section: Discussionmentioning

confidence: 99%

Expression profile of mRNAs and miRNAs related to mitogen-activated kinases in HaCaT cell culture treated with lipopolysaccharide a and adalimumab

Wójcik,

Plata-Babula,

Głowaczewska

et al. 2024

Cell Cycle

View full text Add to dashboard Cite

Studies indicate that mitogen-activated protein kinases (MAPKs) exhibit activation and overexpression within psoriatic lesions. This study aimed to investigate alterations in the expression patterns of genes encoding MAPKs and microRNA (miRNA) molecules that potentially regulate their expression in human adult low-calcium high-temperature (HaCaT) keratinocytes when exposed to bacterial lipopolysaccharide A (LPS) and adalimumab. HaCaT cells underwent treatment with 1 µg/mL LPS for 8 hours, followed by treatment with 8 µg/mL adalimumab for 2, 8, or 24 hours. Untreated cells served as controls. The molecular analysis involved microarray, quantitative real-time polymerase chain reaction (RTqPCR), and enzyme-linked immunosorbent assay (ELISA) analyses. Changes in the expression profile of seven mRNAs: dual specificity phosphatase 1 ( DUSP1) , dual specificity phosphatase 3 ( DUSP3) , dual specificity phosphatase 4 ( DUSP4) , mitogen-activated protein kinase 9 ( MAPK9) , mitogen-activated protein kinase kinase kinase 2 ( MAP3K2) , mitogen-activated protein kinase kinase 2 ( MAP2K2), and MAP kinase-activated protein kinase 2 (MAPKAPK2 , also known as MK2) in cell culture exposed to LPS or LPS and the drug compared to the control. It was noted that miR-34a may potentially regulate the activity of DUSP1 , DUSP3 , and DUSP4 , while miR-1275 is implicated in regulating MAPK9 expression. Additionally, miR-382 and miR-3188 are potential regulators of DUSP4 levels, and miR-200-5p is involved in regulating MAPKAPK2 and MAP3K2 levels. Thus, the analysis showed that these mRNA molecules and the proteins and miRNAs they encode appear to be useful molecular markers for monitoring the efficacy of adalimumab therapy.

show abstract

Section: Discussionmentioning

confidence: 99%